Please assess the completion status of the following clinical trial:

Trial Title: Physical Conditioning and Decitabine for Newly Diagnosed AML Patients Age ≥ 60

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of AML including de novo, secondary, or with an antecedent hematologic disorder (AHD) according to the World Health Organization (WHO) criteria~* Age ≥ 60 years~* Patient not eligible for (immediate) standard induction chemotherapy based on the opinion of the treating physician and the frailty score~* Provide signed written informed consent~* Be able to comply with study procedures and follow-up examinations~* Adequate heart function with echocardiogram demonstrating ejection fraction ≥ 45% with no evidence of systolic dysfunction~* Adequate renal and hepatic function:~  * Total bilirubin ≤ 2x institutional Upper Limit of Normal (ULN); and~ * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3x ULN; and~ * Serum creatinine ≤ 2 times the upper limit of normal~* ECOG performance \< 4~* Patients with a history of carcinoma in remission (on no therapy or on hormonal therapy for the adjuvant treatment of breast carcinoma or prostate carcinoma) are included in the study.~Exclusion Criteria:~* Diagnosis of acute promyelocytic leukemia (APL, French-American-British \[FAB\] classification M3 or WHO classification of APL with t(15;17)(q22;q12)), (PML/retinoic acid receptor alpha \[RARa\] and variants)~* Prior treatment with decitabine for myelodysplastic syndrome (MDS) or AML~* Relapsed or refractory AML~* Rapidly doubling white cell count uncontrolled with hydroxyurea~* Coronary artery disease with angina limiting exercise capability~* Joint disease limiting exercise capability~* Investigational agent received within 30 days prior to the first dose of study drug. If received any investigational agent prior to this time point, drug-related toxicities must have recovered to Grade 2 or less prior to first dose of study drug~* Psychiatric disorders that would interfere with consent, study participation, or follow-up~* Systemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment)~* Any other severe concurrent disease, or serious organ dysfunction or disease involving the heart, kidney, liver, or other organ system that may place the patient at undue risk to undergo the proposed therapy~* No social support or inability to attend study-related visits~* Carcinoma requiring systemic chemotherapy or radiation therapy

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Decitabine and Exercise (Type: EXPERIMENTAL): 8-week program of physical conditioning and decitabine treatment in newly diagnosed AML patients ≥ 60 years of age who are not candidates for standard induction chemotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues